Encorafenib — a new agent for advanced-stage disease
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-018-0019-x
Abstract: Anti-angiogenic therapy, predominantly with the anti-VEGF antibody bevacizumab, has not been shown to improve the survival of patients with breast cancer. 70% of patients with this disease are overweight or obese; now, data from 99… read more here.
Keywords: agent advanced; new agent; encorafenib new; stage disease ... See more keywords
Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Antimicrobial Chemotherapy"
DOI: 10.1093/jac/dkz267
Abstract: Abstract Background Despite intensive treatment regimens, the outcome of Mycobacterium abscessus infections is extremely poor and thus novel treatment regimens are needed. Although tigecycline seems to be one of the best options currently available, its… read more here.
Keywords: omadacycline; treatment; abscessus; new agent ... See more keywords